BACKGROUND: Inflammatory breast cancer (IBC) is a lethal form of breast cancer with unknown etiology. A higher frequency of IBC and a more aggressive IBC phenotype was reported in Egypt than in the United States. This difference in disease frequency and presentation might be related to molecular epidemiologic factors. METHODS: We used tumor blocks and demographic, epidemiologic, and clinical data of 48 IBC patients from Egypt and 12 patients from the United States. We counted tumor emboli in tumors before and after immunohistochemical staining with lymphatic vessel endothelial receptor-1 (LYVE-1), and measured the expression of RhoC GTPase protein in the two groups. RESULTS: Erythema, edema, and peau d'orange were found in 77% of the Egyptian patients as compared with 29% found in the US patients (P=0.02). The number of tumor emboli was significantly higher in tumors from Egypt (mean+/-SD, 14.1+/-14.0) than in the tumors from the United States (5.0+/-4.0, P=0.01). The number of tumor emboli in LYVE-1 positive vessels was higher in tumors from Egypt (3.5+/-2.8) than tumors from the United States (1.6+/-0.5, P=0.15). We detected a high level of RhoC in 87% of the tumors from Egypt and 14% of the tumors from the United States (P=0.0003). CONCLUSION: Patients from Egypt have a more aggressive form of IBC than those in the United States. Our analysis of IBC patients shows that distinct molecular phenotypes can be found when these two study populations are compared. Future studies should explore the epidemiologic and environmental exposures and the genetic factors that might lead to the different clinical and molecular features of IBC in patients from these two countries.
BACKGROUND: Inflammatory breast cancer (IBC) is a lethal form of breast cancer with unknown etiology. A higher frequency of IBC and a more aggressive IBC phenotype was reported in Egypt than in the United States. This difference in disease frequency and presentation might be related to molecular epidemiologic factors. METHODS: We used tumor blocks and demographic, epidemiologic, and clinical data of 48 IBC patients from Egypt and 12 patients from the United States. We counted tumor emboli in tumors before and after immunohistochemical staining with lymphatic vessel endothelial receptor-1 (LYVE-1), and measured the expression of RhoC GTPase protein in the two groups. RESULTS:Erythema, edema, and peau d'orange were found in 77% of the Egyptian patients as compared with 29% found in the US patients (P=0.02). The number of tumor emboli was significantly higher in tumors from Egypt (mean+/-SD, 14.1+/-14.0) than in the tumors from the United States (5.0+/-4.0, P=0.01). The number of tumor emboli in LYVE-1 positive vessels was higher in tumors from Egypt (3.5+/-2.8) than tumors from the United States (1.6+/-0.5, P=0.15). We detected a high level of RhoC in 87% of the tumors from Egypt and 14% of the tumors from the United States (P=0.0003). CONCLUSION:Patients from Egypt have a more aggressive form of IBC than those in the United States. Our analysis of IBC patients shows that distinct molecular phenotypes can be found when these two study populations are compared. Future studies should explore the epidemiologic and environmental exposures and the genetic factors that might lead to the different clinical and molecular features of IBC in patients from these two countries.
Authors: Guenther Gruber; Michele Ciriolo; Hans Joerg Altermatt; Stefan Aebi; Gilles Berclaz; Richard H Greiner Journal: Int J Cancer Date: 2004-03 Impact factor: 7.396
Authors: Kenneth W Hance; William F Anderson; Susan S Devesa; Heather A Young; Paul H Levine Journal: J Natl Cancer Inst Date: 2005-07-06 Impact factor: 13.506
Authors: K L van Golen; S Davies; Z F Wu; Y Wang; C D Bucana; H Root; S Chandrasekharappa; M Strawderman; S P Ethier; S D Merajver Journal: Clin Cancer Res Date: 1999-09 Impact factor: 12.531
Authors: Quintin Pan; Li Wei Bao; Celina G Kleer; Michael S Sabel; Kent A Griffith; Theodoros N Teknos; Sofia D Merajver Journal: Cancer Res Date: 2005-09-15 Impact factor: 12.701
Authors: Ilse Van der Auwera; Steven J Van Laere; Gert G Van den Eynden; Ina Benoy; Peter van Dam; Cecile G Colpaert; Stephen B Fox; Helen Turley; Adrian L Harris; Eric A Van Marck; Peter B Vermeulen; Luc Y Dirix Journal: Clin Cancer Res Date: 2004-12-01 Impact factor: 12.531
Authors: Celina G Kleer; Kenneth L van Golen; Yanhong Zhang; Zhi-Fen Wu; Mark A Rubin; Sofia D Merajver Journal: Am J Pathol Date: 2002-02 Impact factor: 4.307
Authors: Amr S Soliman; Xuemei Wang; John DiGiovanni; Saad Eissa; Magda Morad; Sury Vulimiri; Khaled G Mahgoub; Dennis A Johnston; Kim-Anh Do; Ibrahim A Seifeldin; Paolo Boffetta; Melissa L Bondy Journal: Environ Res Date: 2003-06 Impact factor: 6.498
Authors: Amr Soliman; Katharine Allen; An-Chi Lo; Mousumi Banerjee; Ahmed Hablas; Abdellatif Benider; Nadya Benchekroun; Salwa Samir; Hoda G Omar; Sofia Merajver; Patricia Mullan Journal: Int Electron J Health Educ Date: 2009-01
Authors: Nabila Chaher; Hugo Arias-Pulido; Nadija Terki; Clifford Qualls; Kamel Bouzid; Claire Verschraegen; Anne Marie Wallace; Melanie Royce Journal: Breast Cancer Res Treat Date: 2011-03-01 Impact factor: 4.872
Authors: Brooke Spencer; Mousumi Banerjee; Sherif Omar; Hussein Khaled; Nayera Anwar; Mohamed S Zaghloul; Saad Eissa; Celina G Kleer; Subhojit Dey; Sofia D Merajver; Amr S Soliman Journal: Breast J Date: 2011-08-09 Impact factor: 2.431
Authors: Ashley M Burson; Amr S Soliman; Twalib A Ngoma; Julius Mwaiselage; P Ogweyo; Mohab S Eissa; Subhojit Dey; Sofia D Merajver Journal: Breast Dis Date: 2010
Authors: Mozaffarul Islam; Giant Lin; John C Brenner; Quintin Pan; Sofia D Merajver; Yanjun Hou; Pawan Kumar; Theodoros N Teknos Journal: Mol Cancer Res Date: 2009-10-27 Impact factor: 5.852
Authors: An-Chi Lo; Ageliki Georgopoulos; Celina G Kleer; Mousumi Banerjee; Sherif Omar; Hussein Khaled; Saad Eissa; Ahmed Hablas; Hoda G Omar; Julie A Douglas; Sofia D Merajver; Amr S Soliman Journal: Breast Date: 2009-01-20 Impact factor: 4.380
Authors: Catherine Schairer; Amr S Soliman; Sherif Omar; Hussein Khaled; Saad Eissa; Farhat Ben Ayed; Samir Khalafallah; Wided Ben Ayoub; Elizabeth D Kantor; Sofia Merajver; Sandra M Swain; Mitchell Gail; Linda Morris Brown Journal: Cancer Med Date: 2013-01-24 Impact factor: 4.452